Complarate (tocilizumab biosimilar) / Generium - LARVOL DELTA

Physicochemical and biological characterization of GNR-087, a Tocilizumab biosimilar. (PubMed, J Pharm Biomed Anal) - "The results of the comparative similarity assessment demonstrate high analytical comparability of GNR-087 and Tocilizumab reference product. GNR-087 (Complarate® drug product) was licensed in the Russian Federation in 2024 for the treatment of rheumatoid arthritis."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers (clinicaltrials.gov) - P1 | N=256 | Active, not recruiting | Sponsor: AO GENERIUM | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2024 ➔ Apr 2025

Enrollment closed • Trial completion date • Trial primary completion date

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers (clinicaltrials.gov) - P1 | N=256 | Recruiting | Sponsor: AO GENERIUM

New P1 trial

A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: AO GENERIUM

New P1 trial

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P3 | N=465 | Completed | Sponsor: AO GENERIUM

New P3 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology